Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer.

Publication Type:

Journal Article


Genetics in medicine : official journal of the American College of Medical Genetics, Volume 15, Issue 3, p.203-11 (2013)


Adult, Aged, Breast Neoplasms, Chemotherapy, Adjuvant, Cost-Benefit Analysis, Decision Making, Decision Trees, Female, Humans, Markov Chains, Middle Aged, Neoplasm Staging, RECURRENCE, transcriptome


New evidence is available regarding the utility of the 21-gene recurrence score assay in guiding chemotherapy use for node-negative, estrogen receptor-positive breast cancer. We applied this evidence in a decision-analytic model to re-evaluate the cost-effectiveness of the assay.